NDAINJECTIONINJECTABLEPriority Review
Approved
Dec 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
Priority Review
PHOTOFRIN (porfimer sodium) by Pinnacle Spine is 12. First approved in 1995.
Drug data last refreshed 7h ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PHOTOFRIN (porfimer sodium) is a photosensitizing agent administered intravenously for photodynamic therapy (PDT), a light-activated cancer treatment. It works through a two-stage process: IV infusion followed by selective illumination with 630 nm laser light, generating singlet oxygen and radical reactions that destroy tumor cells. The mechanism combines selective drug retention in tumors with targeted light delivery, inducing both direct cellular damage and vascular occlusion.
LOE Approaching
Product is approaching loss of exclusivity with minimal linked job openings, indicating a contracting team focused on managed decline rather than growth initiatives.
Mechanism of Action
12.1 Mechanism of Action The cytotoxic and antitumor actions of PHOTOFRIN are light and oxygen dependent. Photodynamic therapy (PDT) with PHOTOFRIN is a two-stage process. The first stage is the intravenous administration of PHOTOFRIN. Clearance from a variety of tissues occurs over 40-72 hours,…
Worked on PHOTOFRIN at Pinnacle Spine? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.